AGILE SCORES IN MASLD AND ALD: EXTERNAL VALIDATION AND THEIR UTILITY IN CLINICAL ALGORITHMS.

[1]  V. de Lédinghen,et al.  Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. , 2024, JAMA.

[2]  F. Ravaioli,et al.  Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis , 2023, Hepatology.

[3]  M. Noureddin,et al.  Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores , 2023, Hepatology communications.

[4]  V. Wong,et al.  Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores , 2022, Journal of hepatology.

[5]  J. Lazarus,et al.  Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice , 2022, JHEP reports : innovation in hepatology.

[6]  G. Infantino,et al.  AGILE 3+ Score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[8]  V. de Lédinghen,et al.  Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. , 2020, Journal of hepatology.

[9]  M. Thiele,et al.  Cost‐Effectiveness of Noninvasive Screening for Alcohol‐Related Liver Fibrosis , 2020, Hepatology.

[10]  R. Loomba,et al.  Advances in non-invasive assessment of hepatic fibrosis , 2020, Gut.

[11]  F. Lammert,et al.  Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. , 2019, Journal of hepatology.

[12]  K. Gurusamy,et al.  Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study , 2019, Hepatology.

[13]  L. Longworth,et al.  Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[14]  W. Rosenberg,et al.  Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease , 2019, BMC Gastroenterology.

[15]  M. Thiele,et al.  Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. , 2018, Gastroenterology.

[16]  Emmanuel A Tsochatzis,et al.  Liver cirrhosis , 2014, The Lancet.

[17]  E. Brunt,et al.  Histopathology of nonalcoholic fatty liver disease. , 2010, World journal of gastroenterology.

[18]  S. Friedman,et al.  Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis , 2010, Hepatology.

[19]  Z. Goodman.  Grading and staging systems for inflammation and fibrosis in chronic liver diseases. , 2007, Journal of hepatology.

[20]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[21]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[22]  R. de Franchis.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.

[23]  A. Feinstein,et al.  High agreement but low kappa: II. Resolving the paradoxes. , 1990, Journal of clinical epidemiology.